Skip to content
Inciteful Med

The Biology of PSP: What’s Happening in the Brain?

Last updated:

Progressive Supranuclear Palsy (PSP) is caused by the abnormal buildup of a protein called tau in the brainstem and basal ganglia. These toxic tau clumps damage brain cells, leading to the hallmark symptoms of balance and vision loss. PSP is rarely inherited directly.

Key Takeaways

  • • PSP is caused by the abnormal folding and clumping of the tau protein in brain cells.
  • • The disease is classified as a 4R tauopathy, meaning the tangles are made of a specific 4-repeat version of tau.
  • • Tau damage is most severe in the basal ganglia and brainstem, which control movement, balance, and vision.
  • • A specific genetic variant called the MAPT H1 haplotype increases susceptibility to PSP, but the disease is rarely directly inherited.
  • • There is currently no conclusive evidence linking PSP to environmental toxins or specific geographic areas.

To understand Progressive Supranuclear Palsy (PSP), it helps to look deep inside the brain’s cells. While the symptoms like falling or vision loss are what you feel on the outside, the cause is a microscopic process involving a protein called tau [1][2].

The Scaffolding Analogy: What is Tau?

Every healthy brain cell (neuron) has an internal skeleton called microtubules. These act like railroad tracks, transporting nutrients and messages throughout the cell [3]. A protein called tau acts like the “railroad ties” or scaffolding that holds these tracks together [3].

In PSP, the tau protein becomes hyperphosphorylated—meaning it changes shape and becomes “sticky” [4][5].

  • The Collapse: When tau becomes sticky, it detaches from the railroad tracks. Without its support, the tracks (microtubules) collapse, and the cell can no longer transport what it needs to survive [4][5].
  • The Tangles: The detached, sticky tau then clumps together into “tangles” called neurofibrillary tangles [6][7]. These tangles are toxic and eventually cause the cell to stop working and die [6][2].

A “4R” Tauopathy

Scientists categorize tau diseases by the specific shape of the tau protein involved. PSP is a 4-repeat (4R) tauopathy [8][9]. This means the protein clumps are made of a specific “4-repeat” version of tau [10][11]. This is different from Alzheimer’s disease, which involves a mix of different tau shapes [10].

Where the Damage Happens

In PSP, these tau tangles don’t just affect neurons; they also build up in “helper” cells called glia [10][12].

  • Tufted Astrocytes: These are star-shaped helper cells that develop a “tufted” or feathered appearance when they are clogged with tau [12][13]. They are a “smoking gun” for PSP and are not found in other similar diseases [12][14].
  • Key Brain Regions: The damage is most severe in the basal ganglia (which controls movement) and the brainstem (which controls balance and eye movement) [15][16]. This explains why balance and vision are often the first things to change [17].

Genetics: The MAPT H1 Haplotype

A common question is: “Did I inherit this, and will I pass it on?” For the vast majority of people, PSP is sporadic, meaning it happens by chance and is not directly passed down through families [18].

However, researchers have found a genetic “risk factor” called the MAPT H1 haplotype [18][19].

  • What it is: Think of this as a specific “version” of the tau gene that about 95% of people with PSP carry [18].
  • What it means: Having this gene version doesn’t cause PSP (many healthy people have it too), but it makes a person more susceptible to the disease [20][19].

Environmental Factors

Many families wonder if a specific toxin, job, or location caused the disease. Currently, there is no conclusive evidence linking PSP to environmental toxins, pesticides, heavy metals, or specific geographic “clusters” [21][22]. While scientists continue to study these possibilities, the current consensus is that the disease likely results from a complex mix of genetics and aging rather than a single external cause [23][22].

Return to the Main Guide

Frequently Asked Questions

What is the role of tau protein in PSP?
In PSP, a protein called tau changes shape, becomes sticky, and forms toxic clumps in the brain. This causes the internal structure of brain cells to collapse, preventing them from transporting nutrients and functioning properly.
Is Progressive Supranuclear Palsy hereditary?
For the vast majority of people, PSP occurs randomly and is not passed down directly through families. While a genetic risk factor called the MAPT H1 haplotype is common in people with PSP, having this variant does not mean you will definitely develop the disease.
Why does PSP affect balance and vision first?
The tau protein tangles in PSP primarily build up in the basal ganglia and the brainstem. Because these specific areas of the brain control movement, balance, and eye movements, these functions are typically the first to be affected by the disease.
What are tufted astrocytes in PSP?
Tufted astrocytes are star-shaped support cells in the brain that have become clogged with tau protein. They are a unique biological hallmark of PSP and help pathologists distinguish it from other similar brain diseases.
Can environmental toxins or where I live cause PSP?
Currently, there is no conclusive evidence linking PSP to environmental toxins, pesticides, heavy metals, or specific geographic locations. Researchers believe the disease is a complex mix of genetics and aging rather than a single external cause.

Questions for Your Doctor

  • • Could you explain how the H1/H1 variant found in my tests (if applicable) relates to my specific symptoms?
  • • Is there any benefit to me or my family in pursuing further genetic testing?
  • • Can you show me on my MRI where the brainstem and basal ganglia are affected?
  • • Are there any clinical trials currently targeting the 4R tau protein that I might be eligible for?

Questions for You

  • • Did you grow up or work in a specific geographic area that you're concerned might be a 'cluster' for this disease? (Current research says this is unlikely, but it's helpful for your doctor to know.)
  • • Are there any family members who have had similar symptoms of balance or vision loss, even if they were diagnosed with something else?
  • • How does understanding the 'collapsing scaffolding' analogy change how you think about your daily symptoms?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Inflammatory and Neurotrophic Factors and Their Connection to Quality of Life in Progressive Supranuclear Palsy-Single-Center Study.

    Markiewicz M, Migda B, Otto-Ślusarczyk D, et al.

    International journal of molecular sciences 2025; (26(24)) doi:10.3390/ijms262412122.

    PMID: 41465547
  2. 2

    [Atypical Parkinson's syndrome in old age].

    Iglseder B, Lange R

    Zeitschrift fur Gerontologie und Geriatrie 2022; (55(5)):421-430 doi:10.1007/s00391-022-02077-9.

    PMID: 35748931
  3. 3

    Tau in neurodegenerative disease.

    Gao YL, Wang N, Sun FR, et al.

    Annals of translational medicine 2018; (6(10)):175 doi:10.21037/atm.2018.04.23.

    PMID: 29951497
  4. 4

    Human Tau Isoforms and Proteolysis for Production of Toxic Tau Fragments in Neurodegeneration.

    Boyarko B, Hook V

    Frontiers in neuroscience 2021; (15()):702788 doi:10.3389/fnins.2021.702788.

    PMID: 34744602
  5. 5

    Structure of NFT: Biochemical Approach.

    Hasegawa M

    Advances in experimental medicine and biology 2019; (1184()):23-34 doi:10.1007/978-981-32-9358-8_2.

    PMID: 32096025
  6. 6

    Understanding Tau pathology: Insights from animal models.

    Zhang H, Pan MT, Li YX, et al.

    Zoological research 2025; (46(5)):1244-1258 doi:10.24272/j.issn.2095-8137.2025.077.

    PMID: 41017406
  7. 7

    Progressive supranuclear palsy: an updated approach on diagnosis, treatment, risk factors and outlook in Mexico.

    Gómez-Virgilio L, Gutiérrez-Malacara AI, Rivera-Osorio J, et al.

    Gaceta medica de Mexico 2024; (160(4)):374-383 doi:10.24875/GMM.M24000930.

    PMID: 39832321
  8. 8

    Fibrillation and molecular characteristics are coherent with clinical and pathological features of 4-repeat tauopathy caused by MAPT variant G273R.

    Sandberg A, Ling H, Gearing M, et al.

    Neurobiology of disease 2020; (146()):105079 doi:10.1016/j.nbd.2020.105079.

    PMID: 32961270
  9. 9

    Severity dependent distribution of impairments in PSP and CBS: Interactive visualizations.

    Brittain C, McCarthy A, Irizarry MC, et al.

    Parkinsonism & related disorders 2019; (60()):138-145 doi:10.1016/j.parkreldis.2018.08.025.

    PMID: 30201421
  10. 10

    Molecular Processing of Tau Protein in Progressive Supranuclear Palsy: Neuronal and Glial Degeneration.

    Martínez-Maldonado A, Ontiveros-Torres MÁ, Harrington CR, et al.

    Journal of Alzheimer's disease : JAD 2021; (79(4)):1517-1531 doi:10.3233/JAD-201139.

    PMID: 33459640
  11. 11

    The Role of Tau Proteoforms in Health and Disease.

    Waheed Z, Choudhary J, Jatala FH, et al.

    Molecular neurobiology 2023; (60(9)):5155-5166 doi:10.1007/s12035-023-03387-8.

    PMID: 37266762
  12. 12

    Astrocyte tau deposition in progressive supranuclear palsy is associated with dysregulation of MAPT transcription.

    Jackson RJ, Melloni A, Fykstra DP, et al.

    Acta neuropathologica communications 2024; (12(1)):132 doi:10.1186/s40478-024-01844-6.

    PMID: 39138580
  13. 13

    Cell-specific mitochondrial response in progressive supranuclear palsy.

    Sackmann V, Nassir N, Tanikawa S, et al.

    Mitochondrion 2025; (84()):102043 doi:10.1016/j.mito.2025.102043.

    PMID: 40254117
  14. 14

    [Neuropathology of the Neurodegenerative Diseases].

    Iwasaki Y

    Brain and nerve = Shinkei kenkyu no shinpo 2024; (76(4)):343-351 doi:10.11477/mf.1416202611.

    PMID: 38589279
  15. 15

    Chameleons and mimics: Progressive supranuclear palsy and corticobasal degeneration.

    Mimuro M, Yoshida M

    Neuropathology : official journal of the Japanese Society of Neuropathology 2020; (40(1)):57-67 doi:10.1111/neup.12590.

    PMID: 31515852
  16. 16

    Pathological study of progressive supranuclear palsy the cases with mutations in Bassoon.

    Wakita M, Yaguchi H, Otuski M, et al.

    Neuropathology : official journal of the Japanese Society of Neuropathology 2025; (45(2)):140-152 doi:10.1111/neup.13009.

    PMID: 39478416
  17. 17

    Progressive supranuclear palsy, a case report.

    Ortiz A, Troya F, de Vera J, Vázquez E

    Archivos de la Sociedad Espanola de Oftalmologia 2024; (99(7)):304-308 doi:10.1016/j.oftale.2024.05.004.

    PMID: 38768849
  18. 18

    MAPT haplotype-associated transcriptomic changes in progressive supranuclear palsy.

    Ressler HW, Humphrey J, Vialle RA, et al.

    Acta neuropathologica communications 2024; (12(1)):135 doi:10.1186/s40478-024-01839-3.

    PMID: 39154163
  19. 19

    iPS Cell-Based Model for MAPT Haplotype as a Risk Factor for Human Tauopathies Identifies No Major Differences in TAU Expression.

    Strauß T, Marvian-Tayaranian A, Sadikoglou E, et al.

    Frontiers in cell and developmental biology 2021; (9()):726866 doi:10.3389/fcell.2021.726866.

    PMID: 34532319
  20. 20

    MAPT Subhaplotypes in Different Progressive Supranuclear Palsy Phenotypes.

    Gagliardi M, Procopio R, Felicetti A, et al.

    Biomedicines 2025; (13(6)) doi:10.3390/biomedicines13061405.

    PMID: 40564124
  21. 21

    Luxembourg Parkinson's study -comprehensive baseline analysis of Parkinson's disease and atypical parkinsonism.

    Pavelka L, Rawal R, Ghosh S, et al.

    Frontiers in neurology 2023; (14()):1330321 doi:10.3389/fneur.2023.1330321.

    PMID: 38174101
  22. 22

    Quality of life in patients with progressive supranuclear palsy: a review of literature and implications for practice.

    Markiewicz M, Madetko-Alster N, Alster P

    Frontiers in neurology 2024; (15()):1476488 doi:10.3389/fneur.2024.1476488.

    PMID: 39634776
  23. 23

    Genetic and Epigenetic Constructs of Progressive Supranuclear Palsy.

    Debnath M, Dey S, Sreenivas N, et al.

    Annals of neurosciences 2022; (29(2-3)):177-188 doi:10.1177/09727531221089396.

    PMID: 36419517

This page explains the underlying biology of Progressive Supranuclear Palsy for educational purposes only. It does not replace professional medical advice, diagnosis, or treatment from a qualified neurologist.

Stay up to date

Get notified when new research about Progressive supranuclear palsy is published.

No spam. Unsubscribe anytime.